{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:07:25Z","timestamp":1761541645724,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.cgh.2006.09.036","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:27:03Z","timestamp":1168424823000},"page":"285-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["New and Emerging Treatment of Chronic Hepatitis B"],"prefix":"10.1016","volume":"5","author":[{"given":"Emmet B.","family":"Keeffe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2006.09.036_bib1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection: natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","article-title":"Viral hepatitis B","volume":"362","author":"Lai","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2006.09.036_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.09.036_bib6","first-page":"754A","article-title":"Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy","volume":"42","author":"Hadziyannis","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","article-title":"Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study","volume":"36","author":"Brunetto","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2006.09.036_bib8","unstructured":"Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther In press."},{"key":"10.1016\/j.cgh.2006.09.036_bib9","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib10","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2006.09.036_bib11","first-page":"149","article-title":"Interferon therapy improves prognosis in patients with HBeAg positive chronic hepatitis B","volume":"42","author":"Lin","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2006.09.036_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2893.2004.00512.x","article-title":"Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B","volume":"11","author":"Lin","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cgh.2006.09.036_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B","volume":"39","author":"van Zonneveld","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1572-0241.1998.00272.x","article-title":"Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis","volume":"93","author":"Fattovich","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2006.09.036_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2006.09.036_bib16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.09.036_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2893.2005.00603.x","article-title":"The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B","volume":"12","author":"Yuan","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cgh.2006.09.036_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.10559","article-title":"Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers","volume":"72","author":"Tang","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.cgh.2006.09.036_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","article-title":"Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men","volume":"97","author":"Yu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cgh.2006.09.036_bib20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.41.7.1444","article-title":"Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus","volume":"41","author":"Innaimo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2006.09.036_bib21","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/AAC.42.12.3200","article-title":"In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir","volume":"42","author":"Seifer","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2006.09.036_bib22","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1128\/AAC.46.8.2525-2532.2002","article-title":"Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro","volume":"46","author":"Levine","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2006.09.036_bib23","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1086\/324003","article-title":"Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection","volume":"184","author":"Colonno","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cgh.2006.09.036_bib24","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1128\/JVI.79.9.5819-5832.2005","article-title":"Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection","volume":"79","author":"Foster","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.cgh.2006.09.036_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.46.1.82-88.2002","article-title":"Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication","volume":"46","author":"Marion","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2006.09.036_bib26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/jhep.2001.26815","article-title":"Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection","volume":"34","author":"de Man","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib27","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/gast.2002.37058","article-title":"Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection","volume":"123","author":"Lai","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.09.036_bib28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","article-title":"A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients","volume":"129","author":"Chang","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.09.036_bib29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib31","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"year":"2006","series-title":"Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients","author":"Chang","key":"10.1016\/j.cgh.2006.09.036_bib32"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2006.09.036_bib33","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8278(06)80046-2","article-title":"Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg- chronic hepatitis B patients (study ETV-027)","volume":"130","author":"Shouval","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2006.09.036_bib34","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(06)80081-4","article-title":"Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg+ chronic hepatitis B patients (ETV-026)","volume":"130","author":"Yurdaydin","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2006.09.036_bib35","first-page":"A573","article-title":"Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients","volume":"42","author":"Colonno","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib36","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200161150-00013","article-title":"Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.cgh.2006.09.036_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2006.09.036_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib41","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib43","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.20695","article-title":"Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B","volume":"41","author":"Chan","year":"2005","journal-title":"Hepatology"},{"year":"2006","series-title":"Durability of response to peginterferon alfa-2a (40 KD) (PEGASYS) in Asian patients with HBeAg-positive chronic hepatitis B: 12 month follow-up data from a large, randomized study","author":"Lau","key":"10.1016\/j.cgh.2006.09.036_bib44"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2006.09.036_bib45","first-page":"A580","article-title":"Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2a (40KD) (Pegasys) monotherapy for HBeAg-negative chronic hepatitis B","volume":"42","author":"Marcellin","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2005.02.017","article-title":"Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study","volume":"43","author":"Gish","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2006.09.036_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2006.09.036_bib48","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1128\/AAC.50.5.1642-1648.2006","article-title":"Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B","volume":"50","author":"Lim","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cgh.2006.09.036_bib49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350400900611","article-title":"Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection","volume":"9","author":"Korba","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cgh.2006.09.036_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hep.20257","article-title":"A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B","volume":"40","author":"Marcellin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib51","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21166","article-title":"A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/14787210.3.4.489","article-title":"Telbivudine: an upcoming agent for chronic hepatitis B","volume":"3","author":"Yuen","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cgh.2006.09.036_bib53","first-page":"232","article-title":"Telbivudine\/torcitabine Idenix\/Novartis","volume":"5","author":"Hodge","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.cgh.2006.09.036_bib54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.20374","article-title":"A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection","volume":"40","author":"Lai","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2006.09.036_bib56","first-page":"A748","article-title":"Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the International Phase III Globe Trial","volume":"42","author":"Lai","year":"2005","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2006.09.036_bib57","first-page":"A173","article-title":"Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: results of a phase I\/II clinical trial","volume":"40","author":"Lai","year":"2004","journal-title":"Hepatology"},{"year":"2006","series-title":"The antiviral efficacy of telbivudine is consistent across hepatitis B patient subgroups: results from the GOLBE study","author":"Lim","key":"10.1016\/j.cgh.2006.09.036_bib58"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2006.09.036_bib59","first-page":"16","article-title":"Final results of a phase I\/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B","volume":"42","author":"Lim","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2006.09.036_bib60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.21055","article-title":"Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients","volume":"43","author":"Benhamou","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib61","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection","volume":"40","author":"van Bommel","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2006.09.036_bib62","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus","volume":"189","author":"Dore","year":"2004","journal-title":"J Infect Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356506009724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356506009724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:30Z","timestamp":1761541170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356506009724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1542356506009724"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2006.09.036","relation":{},"ISSN":["1542-3565"],"issn-type":[{"type":"print","value":"1542-3565"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Emerging Treatment of Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2006.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}